Ibipanto Injection contains Pantoprazole 40 mg, a proton pump inhibitor used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive stomach acid production. Pantoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step in gastric acid production. This results in prolonged reduction of gastric acidity, promoting healing of acid-related lesions and relief of associated symptoms such as heartburn and acid regurgitation. Ibipanto Injection is administered intravenously, making it suitable for patients unable to take oral medication or requiring rapid acid suppression. The recommended dosage and duration of therapy depend on the clinical condition and patient response. Common adverse effects may include headache, diarrhea, nausea, and injection site reactions, though it is generally well tolerated. Caution is advised in patients with hepatic impairment, and monitoring is recommended during prolonged use. Ibipanto Injection should be used under medical supervision, with consideration of potential drug interactions and contraindications. It is essential to follow prescribed dosing to ensure efficacy and minimize risks.